

D ThaÃ§i

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1683500/publications.pdf>

Version: 2024-02-01

221
papers

14,609
citations

24978

57
h-index

22102

113
g-index

254
all docs

254
docs citations

254
times ranked

9608
citing authors

#	ARTICLE	IF	CITATIONS
1	Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2014, 371, 130-139.	13.9	1,148
2	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 239-254.	0.6	577
3	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 400-409.	0.6	472
4	Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet</i> , The, 2016, 387, 40-52.	6.3	471
5	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE) Tj ETQq1 10,784314,rgBT /Ove	6.3	428
6	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 729-735.	0.6	397
7	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t. <i>British Journal of Dermatology</i> , 2018, 178, 1083-1101.	1.4	380
8	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2016, 175, 273-286.	1.4	378
9	Psoriasis: a possible risk factor for development of coronary artery calcification. <i>British Journal of Dermatology</i> , 2007, 156, 271-276.	1.4	326
10	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet</i> , The, 2017, 389, 2317-2327.	6.3	316
11	Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. <i>New England Journal of Medicine</i> , 2018, 379, 1313-1321.	13.9	301
12	Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. <i>Lancet</i> , The, 2021, 397, 2151-2168.	6.3	259
13	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 60-69.e9.	0.6	258
14	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. <i>British Journal of Dermatology</i> , 2015, 173, 949-961.	1.4	253
15	Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 877-884.	1.5	242
16	Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1101-1112.	13.9	239
17	Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. <i>British Journal of Dermatology</i> , 2015, 173, 930-939.	1.4	236
18	Psoriasis patients show signs of insulin resistance. <i>British Journal of Dermatology</i> , 2007, 157, 1249-1251.	1.4	227

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1282-1293.	0.6	214
20	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. <i>British Journal of Dermatology</i> , 2012, 168, no-no.	1.4	199
21	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 576-586.	6.3	198
22	Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (<sc>SCULPTURE</sc> Extension Study). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1507-1514.	1.3	160
23	Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. <i>British Journal of Dermatology</i> , 2008, 159, 1348-1356.	1.4	155
24	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 928-938.	1.4	155
25	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 377-388.	0.6	155
26	Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1054-1062.	0.3	150
27	Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for 156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 310-317.e1.	0.6	148
28	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 841-850.	0.6	135
29	Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 443-456.	3.3	130
30	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and 2). <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 43, 1027-1035.	0.0	127
31	Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. <i>Archives of Dermatological Research</i> , 2015, 307, 875-883.	1.1	124
32	IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. <i>Frontiers in Immunology</i> , 2019, 10, 3096.	2.2	122
33	Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). <i>Journal of Dermatological Science</i> , 2019, 94, 266-275.	1.0	121
34	Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 40-49.	6.3	120
35	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. <i>British Journal of Dermatology</i> , 2013, 168, 402-411.	1.4	118
36	Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase 3 open-label trial and subsequent phase 3 open-label extension. <i>British Journal of Dermatology</i> , 2020, 182, 85-96.	1.4	111

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 131.	2.0	110
38	Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1187-1193.	1.3	106
39	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1235-1242.	6.7	104
40	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks. <i>British Journal of Dermatology</i> , 2020, 182, 605-617.	1.4	103
41	Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 476-485.	1.3	101
42	A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. <i>British Journal of Dermatology</i> , 2010, 163, 402-411.	1.4	99
43	Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e376-83.	1.3	93
44	Patient-relevant treatment goals in psoriasis. <i>Archives of Dermatological Research</i> , 2016, 308, 69-78.	1.1	92
45	IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. <i>Journal of Autoimmunity</i> , 2019, 96, 104-112.	3.0	85
46	Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis – A retrospective study (FUTURE). <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 603-610.	0.4	82
47	Topical Methyl Aminolevulinic Acid Photodynamic Therapy Using Red Light-Emitting Diode Light for Multiple Actinic Keratoses. <i>Dermatologic Surgery</i> , 2009, 35, 586-592.	0.4	81
48	Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. <i>Clinics in Dermatology</i> , 2010, 28, 52-56.	0.8	79
49	Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 700-708.	1.3	78
50	Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 567-577.	3.3	78
51	Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. <i>Contact Dermatitis</i> , 2003, 49, 80-84.	0.8	76
52	Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 353-360.	1.3	75
53	Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 420-427.	1.3	70
54	Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). <i>British Journal of Dermatology</i> , 2015, 173, 777-787.	1.4	67

#	ARTICLE	IF	CITATIONS
55	Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 1183-1188.	1.5	66
56	Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. <i>Archives of Dermatological Research</i> , 2011, 303, 381-388.	1.1	66
57	Calcipotriol Solution for the Treatment of Scalp Psoriasis: Evaluation of Efficacy, Safety and Acceptance in 3,396 Patients. <i>Dermatology</i> , 2001, 203, 153-156.	0.9	65
58	Leflunomide Improves Psoriasis in Patients with Psoriatic Arthritis: An In-Depth Analysis of Data from the TOPAS Study. <i>Dermatology</i> , 2006, 212, 238-249.	0.9	59
59	Occlusive Treatment of Chronic Hand Dermatitis with Pimecrolimus Cream 1% Results in Low Systemic Exposure, Is Well Tolerated, Safe, and Effective. <i>Dermatology</i> , 2003, 207, 37-42.	0.9	58
60	Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1162-1170.e3.	0.6	57
61	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018, 179, 615-622.	1.4	57
62	Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis. <i>British Journal of Dermatology</i> , 2019, 181, 1254-1264.	1.4	57
63	Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 734-739.	0.6	56
64	Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 51-64.	3.3	56
65	Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 410-419.e6.	0.6	55
66	Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. <i>British Journal of Dermatology</i> , 2021, 185, 323-334.	1.4	55
67	Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. <i>British Journal of Dermatology</i> , 2017, 177, 1033-1042.	1.4	54
68	The role of the microbiome in psoriasis: moving from disease description to treatment selection?. <i>British Journal of Dermatology</i> , 2018, 178, 1020-1027.	1.4	54
69	Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model. <i>Toxicology in Vitro</i> , 2008, 22, 747-759.	1.1	53
70	Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. <i>British Journal of Dermatology</i> , 2019, 181, 80-87.	1.4	49
71	Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 900-906.	1.3	48
72	Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. <i>British Journal of Dermatology</i> , 2017, 177, 1024-1032.	1.4	48

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1012-1020.	1.3	47
74	The German National Program on Psoriasis Health Care 2005–2015: results and experiences. <i>Archives of Dermatological Research</i> , 2016, 308, 389-400.	1.1	47
75	Body-Weight-Independent Dosing of Cyclosporine Micro-Emulsion and Three Times Weekly Maintenance Regimen in Severe Psoriasis. <i>Dermatology</i> , 2002, 205, 383-388.	0.9	46
76	A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 34-40.	0.6	45
77	Dupilumab provides favourable long-term safety and efficacy in children aged 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. <i>British Journal of Dermatology</i> , 2021, 184, 857-870.	1.4	45
78	Recommendations for detection of individual risk for comorbidities in patients with psoriasis. <i>Archives of Dermatological Research</i> , 2013, 305, 91-98.	1.1	44
79	Topical calcineurin inhibitors for the treatment of vulvar dermatoses. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2009, 146, 22-29.	0.5	42
80	Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e191-e192.	1.3	42
81	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. <i>British Journal of Dermatology</i> , 2019, 181, 358-365.	1.4	42
82	Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1040-1046.	1.3	40
83	Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1269-1277.	0.6	38
84	Subcutaneous Immunotherapy with a Depigmented Polymerized Birch Pollen Extract – A New Therapeutic Option for Patients with Atopic Dermatitis. <i>International Archives of Allergy and Immunology</i> , 2011, 155, 252-256.	0.9	37
85	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 435-444.	1.4	37
86	Long-term topical management of psoriasis: the road ahead. <i>Journal of Dermatological Treatment</i> , 2022, 33, 111-120.	1.1	37
87	Treatment of scabies with 5% permethrin cream: results of a German multicenter study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2006, 4, 407-413.	0.4	35
88	Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. <i>Dermatology and Therapy</i> , 2017, 7, 365-381.	1.4	33
89	Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. <i>British Journal of Dermatology</i> , 2019, 180, 67-75.	1.4	33
90	Use of Calcipotriene Cream (Dovonex Cream) Following Acute Treatment of Psoriasis Vulgaris with the Calcipotriene/Betamethasone Dipropionate Two-Compound Product (Taclonex). <i>American Journal of Clinical Dermatology</i> , 2006, 7, 177-184.	3.3	32

#	ARTICLE	IF	CITATIONS
91	Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. Archives of Dermatological Research, 2008, 300, 101-105.	1.1	31
92	Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis. Rheumatology, 2016, 55, 1791-1795.	0.9	31
93	Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study. Journal of Rheumatology, 2016, 43, 632-639.	1.0	31
94	Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy. Dermatology and Therapy, 2017, 7, 265-279.	1.4	31
95	A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. British Journal of Dermatology, 2020, 182, 869-879.	1.4	31
96	Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1212-1223.e6.	2.0	31
97	Clinical Management of Atopic Eczema with Pimecrolimus Cream 1% (Elidel®) in Paediatric Patients. Dermatology, 2007, 215, 3-17.	0.9	30
98	Cost of illness of psoriasis – results of a German cross-sectional study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 174-180.	1.3	30
99	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy, 2022, 12, 495-510.	1.4	30
100	'Using 'Around' the human skin: What information is concealed in skin odour?. Experimental Dermatology, 2012, 21, 655-659.	1.4	29
101	Topical long-term therapy of psoriasis with vitamin D ₃ analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. JDDG - Journal of the German Society of Dermatology, 2014, 12, 667-682.	0.4	29
102	The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Annals of the Rheumatic Diseases, 2019, 78, 1215-1219.	0.5	29
103	Long-term data in the treatment of psoriasis. British Journal of Dermatology, 2008, 159, 18-24.	1.4	28
104	Red ear syndrome and auricular erythromelalgia: the same condition?. Clinical and Experimental Dermatology, 2009, 34, e626-e628.	0.6	28
105	Diagnosing and treating psoriatic arthritis: an update. British Journal of Dermatology, 2014, 170, 772-786.	1.4	28
106	Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 498-506.	1.3	28
107	Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. British Journal of Dermatology, 2019, 181, 1177-1189.	1.4	28
108	Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatology and Therapy, 2020, 10, 663-670.	1.4	28

#	ARTICLE	IF	CITATIONS
109	Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). <i>Rheumatology</i> , 2018, 57, 1777-1788.	0.9	27
110	Composite Measures in Psoriatic Arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010, 37, 453-461.	1.0	26
111	Improved enantioselective analysis of polyunsaturated hydroxy fatty acids in psoriatic skin scales using high-performance liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 819, 323-328.	1.2	25
112	Oligonucleotides Suppress IL-8 in Skin Keratinocytes In Vitro and Offer Anti-Inflammatory Properties In Vivo. <i>Journal of Investigative Dermatology</i> , 2007, 127, 846-854.	0.3	25
113	Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. <i>European Journal of Dermatology</i> , 2012, 22, 762-769.	0.3	25
114	Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. <i>British Journal of Dermatology</i> , 2018, 179, 1385-1391.	1.4	25
115	Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 310-318.	1.3	25
116	Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). <i>British Journal of Dermatology</i> , 2020, 183, 265-275.	1.4	24
117	Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. <i>British Journal of Dermatology</i> , 2005, 152, 1048-1050.	1.4	23
118	Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2019, 180, 76-85.	1.4	23
119	Successful Treatment of Acrodermatitis Continua of Hallopeau with Sequential Combination of Calcipotriol and Tacrolimus Ointments. <i>Dermatology</i> , 2005, 211, 351-355.	0.9	22
120	Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 741-748.	0.6	22
121	Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 735.	2.0	22
122	Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy. <i>Experimental Dermatology</i> , 2011, 20, 130-133.	1.4	21
123	Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 448-455.	1.3	21
124	Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1271-1284.	1.3	21
125	Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study*. <i>British Journal of Dermatology</i> , 2021, 185, 1160-1168.	1.4	21
126	POS1042...EFFICACY AND SAFETY OF DELUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETIK PSO-1 STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 795.1-796.	0.5	21

#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions – a retrospective evaluation (FACTS). <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 429-435.	0.4	20
128	Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1116-1123.	1.3	20
129	Effectiveness of alitretinoin in severe chronic hand eczema: PASSION, a real-world observational study. <i>Journal of Dermatological Treatment</i> , 2016, 27, 577-583.	1.1	19
130	Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1098-1106.	1.3	19
131	Pictorial representation of illness and self measure (<scp>PRISM</scp>): an effective tool to assess the burden of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2356-2362.	1.3	18
132	Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 709-717.	1.3	17
133	Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey. <i>Rheumatology and Therapy</i> , 2020, 7, 617-637.	1.1	17
134	Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care. <i>PLoS ONE</i> , 2020, 15, e0235091.	1.1	17
135	Alopecia areata development in atopic dermatitis patients treated with dupilumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e612-e613.	1.3	17
136	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2317-2324.	1.1	17
137	Vascular Endothelial Growth Factor C-Induced Lymphangiogenesis Decreases Tumor Interstitial Fluid Pressure and Tumor. <i>Translational Oncology</i> , 2013, 6, 398-404.	1.7	16
138	Importance of basic therapy in psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 415-418.	0.4	16
139	Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the <scp>PROSPECT</scp> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 411-419.	1.3	15
140	Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). <i>British Journal of Dermatology</i> , 2021, 184, 652-662.	1.4	15
141	Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. <i>Paediatric Drugs</i> , 2021, 23, 515-527.	1.3	15
142	Ligation of Î²4 integrins activates PKB/Akt and ERK1/2 by distinct pathways – relevance of the keratin filament. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 940-950.	1.9	14
143	Management of Psoriasis in Africa and the Middle East: A Review of Current Opinion, Practice and Opportunities for Improvement. <i>Journal of International Medical Research</i> , 2011, 39, 1573-1588.	0.4	14
144	Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1405-1409.	0.6	14

#	ARTICLE	IF	CITATIONS
145	Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1608-1616.	1.1	14
146	A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action. <i>Joint Bone Spine</i> , 2021, 88, 105175.	0.8	14
147	Periorale Dermatitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 422-428.	0.4	13
148	Successful Treatment of Refractory Palmoplantar Pustular Psoriasis With Apremilast: A Case Series. <i>Frontiers in Medicine</i> , 2020, 7, 543944.	1.2	13
149	Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2809-2820.	1.3	13
150	Dupilumab for treatment of refractory prurigo nodularis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 618-624.	0.4	12
151	Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 35-41.	1.3	12
152	Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1686-1691.	1.3	12
153	Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials. <i>Journal of the American Association of Nurse Practitioners</i> , 2018, 30, 529-541.	0.5	11
154	General practice recommendations for the topical treatment of psoriasis: a modified-Delphi approach. <i>BJGP Open</i> , 2020, 4, bjgpopen20X101108.	0.9	11
155	Impact on quality of life of alitretinoin in severe chronic hand eczema: FUGETTA real-world study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1261-1270.	0.4	10
156	Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. <i>European Journal of Dermatology</i> , 2020, 30, 267-278.	0.3	10
157	Secukinumab-induced chronic discoid lupus erythematosus. <i>JAAD Case Reports</i> , 2020, 6, 362-364.	0.4	10
158	Prevalence and presumptive triggers of localized bullous pemphigoid. <i>Journal of Dermatology</i> , 2021, 48, 1257-1261.	0.6	10
159	Cutaneous leishmaniasis: Clinical report of two cases and review of the recent literature. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, 770-772.	0.4	9
160	Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 1478-1480.	0.4	9
161	Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2022, 186, 30-39.	1.4	9
162	Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes. <i>Rheumatology and Therapy</i> , 2022, 9, 621-635.	1.1	9

#	ARTICLE	IF	CITATIONS
163	Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00683.	0.6	9
164	Restoration of E-cadherin sensitizes human melanoma cells for apoptosis. <i>Melanoma Research</i> , 2006, 16, 393-403.	0.6	8
165	Percutaneous Absorption of Pimecrolimus Is Not Increased in Patients with Moderate to Severe Atopic Dermatitis when Pimecrolimus Cream 1% Is Applied under Occlusion. <i>Dermatology</i> , 2010, 221, 342-351.	0.9	8
166	<p>Spotlight on Topical Long-Term Management of Plaque Psoriasis</p>. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2020, Volume 13, 495-498.	0.8	8
167	International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. <i>BMJ Open</i> , 2020, 10, e039928.	0.8	8
168	Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of antiâ€œBP180 autoantibodies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 981-987.	1.3	8
169	Documentation of psoriasis in routine care â€œ expert consensus on a German data set. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1463-1475.	0.4	8
170	Complicated mycosis fungoides mimicking facial erysipelas. <i>British Journal of Dermatology</i> , 2005, 152, 1381-1383.	1.4	7
171	Continued treatment with secukinumab is associated with high retention or regain of response. <i>British Journal of Dermatology</i> , 2019, 182, 67-75.	1.4	7
172	Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis â€œ efficacy findings up to week 12. <i>Journal of Dermatological Treatment</i> , 2022, 33, 54-61.	1.1	7
173	Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary. <i>Immunotherapy</i> , 2022, 14, 5-14.	1.0	7
174	A Digital Health Application Allowing a Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Proof-of-Concept Data from a Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 1117.	1.0	7
175	Modeling Pattern Formation in Skin Diseases by a Cellular Automaton. <i>Journal of Investigative Dermatology</i> , 2013, 133, 567-571.	0.3	6
176	Stellenwert der Basistherapie bei Psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 415-418.	0.4	6
177	Seborrhoeic keratosis removal in a multicentre phase I/II clinical trial using a novel topical formulation (BL-5010). <i>British Journal of Dermatology</i> , 2015, 173, 247-249.	1.4	6
178	Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1749-1753.	1.1	6
179	Quality of life and patientâ€™perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixedâ€œdose combination Cal/BD foam: A <i>postâ€œhoc</i> analysis of PSOâ€œLONG. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 60-67.	1.3	6
180	BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020, 4, s28.	0.1	6

#	ARTICLE	IF	CITATIONS
181	Validation of Dermaphot® for the assessment of steroid-induced skin atrophy. Archives of Dermatological Research, 2013, 305, 215-221.	1.1	5
182	Best-practice Indicators in Psoriatic Disease Care. Journal of Rheumatology, 2019, 95, 38-45.	1.0	5
183	Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase). Journal of Drugs in Dermatology, 2021, 20, 436-441.	0.4	5
184	Association between Skin and Joint Involvement in Patients with Psoriatic Arthritis Treated with Adalimumab: Analysis of Data from a German Non-Interventional Study. Dermatology, 2015, 230, 213-221.	0.9	4
185	Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate to severe plaque psoriasis naïve to systemic treatment. British Journal of Dermatology, 2021, 184, 548-550.	1.4	4
186	Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. Dermatology and Therapy, 2021, 11, 2147-2157.	1.4	4
187	Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. SKIN the Journal of Cutaneous Medicine, 2021, 5, s37.	0.1	4
188	Oligonucleotides suppress PKB/Akt and act as superinductors of apoptosis in human keratinocytes. Nucleic Acids Research, 2009, 37, 3850-3864.	6.5	3
189	GRAPPA Fellows Symposium Adjacent to the European Academy of Dermatology and Venereology (EADV) Congress, Istanbul, 2013: A Meeting Report. Journal of Rheumatology, 2014, 41, 1197-1199.	1.0	3
190	Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN the Journal of Cutaneous Medicine, 2022, 6, s4.	0.1	3
191	Detection of human beta defensin-1 and ?2 by RT-competitive multiplex PCR. Archives of Dermatological Research, 2005, 296, 539-542.	1.1	2
192	Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis". Journal of Investigative Dermatology, 2017, 137, 2642-2644.	0.3	2
193	14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2). Journal of the American Academy of Dermatology, 2020, 83, AB16.	0.6	2
194	15026 BMS-986165, an oral selective tyrosine kinase 2 inhibitor: Evaluation of changes in laboratory parameters in response to treatment in a phase 2 trial in psoriasis. Journal of the American Academy of Dermatology, 2020, 83, AB140.	0.6	2
195	High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study. Modern Rheumatology, 2022, 32, 87-95.	0.9	2
196	Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate to severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e709-e711.	1.3	2
197	Heavy Naphthen Oil Exhibits Antipsoriatic Efficacy In Vivo and Antiproliferative as Well as Differentiation-Inducing Effects on Keratinocytes In Vitro. Archives of Dermatology, 2000, 136, 678-679.	1.7	2
198	Tacalcitol in combination with UVB " in vitro effects. Journal of Dermatological Treatment, 1998, 9, S31-S35.	1.1	1

#	ARTICLE	IF	CITATIONS
217	A trial to compare the biologic drug ixekizumab with two other treatments for psoriasis, fumaric acid esters and methotrexate. British Journal of Dermatology, 2020, 182, e138.	1.4	0
218	27464 Bimekizumab vs adalimumab in plaque psoriasis: Higher efficacy translates into improvements in quality of life in the BE SURE multicenter, randomized, double-blinded phase 3 trial. Journal of the American Academy of Dermatology, 2021, 85, AB146.	0.6	0
219	27596 Improvement in absolute psoriasis area and severity index through 5 years of continuous treatment with guselkumab in the VOYAGE 1 trial. Journal of the American Academy of Dermatology, 2021, 85, AB154.	0.6	0
220	26573 Maintenance of response after guselkumab withdrawal in patients with moderate-to-severe psoriasis: A post hoc analysis of the VOYAGE 2 trial. Journal of the American Academy of Dermatology, 2021, 85, AB107.	0.6	0
221	AB1289-HPRâ€¦PERCEPTION OF THE VALUE OF DRUGS ON DIFFERENT MANIFESTATIONS OF PSORIATIC ARTHRITIS BASED ON A MULTI-STAGE EXPERT OPINION SURVEY. Annals of the Rheumatic Diseases, 2020, 79, 1934.2-1935.	0.5	0